Anebulo Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses

3 Months Ended

Sep. 30, 2023

Note 4. Accrued Expenses

Accrued expenses consisted of the following:

Schedule of Accrued Expenses

	September 30, 2023		June 30, 2023
Accrued payroll related expenses	$	116,200	$	190,121
Accrued professional fees		34,411		-
Accrued research and development		-		344,135
Total accrued expenses	$	150,611	$	534,256